Table 2.
Toxicities after CAR-T therapy in all patients.
| Toxicities | n (%) | |
|---|---|---|
| Cytokine-release syndrome grade | ||
| 0 | 8(24.2) | |
| 1-2 | 18(54.5) | |
| 3-5 | 7(21.2) | |
| Immune effect or cell associated neurotoxic syndrome | 3(9.0) | |
| Hematological toxicity | ||
| Neutropenia (III/IV) | 33(100) | |
| Anemia (III/IV) | 23(69.7) | |
| Thrombocytopenia (III/IV) | 30(90.9) | |
| Hemagglutination abnormalities(III/IV) | 12(36.4) | |
| Non-neurological and non-hematological toxicity | ||
| Pyrexia | 26(78.8) | |
| Hypoxia | 12(36.4) | |
| Hypotension | 1(3.0) | |
| Cardiac failure | 2(6.0) | |
| Acute kidney injury | 5(15.2) | |
| Ascites/Hydrothorax | 0(0) | |
| Pneumonia | 4(12.1) | |
| Increase of alanine-aminotransferase | 8(24.2) | |
| Increase of Hyperbilirubinemia | 1(3.0) | |
| Tumor lysis syndrome | 0(0.0) | |